| Cell line name |
DX3-LT5.1 |
| Synonyms |
DX3.LT5.1; DX3 LT5.1; DX3LT5.1; DX3-azaC-LT5.1; LT5.1 |
| Accession |
CVCL_LI22 |
| Resource Identification Initiative |
To cite this cell line use: DX3-LT5.1 (RRID:CVCL_LI22) |
| Comments |
Characteristics: Highly metastatic in mice. Selected for resistance to: ChEBI; CHEBI_2038; 5-azacytidine (5-azaC). Omics: Proteomics; 2DE. Derived from site: Metastatic; Hypodermis; UBERON=UBERON_0002072. |
| Sequence variations |
- Gene deletion; HGNC; HGNC:1787; CDKN2A; Zygosity=Heterozygous (from parent cell line).
- Gene deletion; HGNC; HGNC:1788; CDKN2B; Zygosity=Homozygous (from parent cell line).
|
| Disease |
Melanoma (NCIt: C3224) |
| Species of origin |
Homo sapiens (Human)
(NCBI Taxonomy: 9606) |
| Hierarchy |
Parent: CVCL_5650 (SK-MEL-93 DX-3) Children:
|
| Sex of cell |
Female |
| Age at sampling |
71Y |
| Category |
Cancer cell line |
| Publications | PubMed=2416434 E. Jane Ormerod, Christine A. Everett, Ian R. Hart; Enhanced experimental metastatic capacity of a human tumor line following treatment with 5-azacytidine. Cancer Res. 46:884-890(1986) PubMed=2060182; DOI=10.1007/BF01753726 David J. Easty, Ian R. Hart, Ketan Patel, Clive Seymour, Magdi Habib Yacoub, Albert Domscheit, Siegfried Gunther, Wilhelm Postel, Angelika Gorg, Michael J. Dunn; Changes in protein expression during melanoma differentiation determined by computer analysis of 2-D gels. Clin. Exp. Metastasis 9:221-230(1991) PubMed=7780963 David J. Easty, Brenda A. Guthrie, Kavita Maung, Christine J. Farr, Richard A. Lindberg, Robert J. Toso, Meenhard Herlyn, Dorothy Catherine Bennett; Protein B61 as a new growth factor: expression of B61 and up-regulation of its receptor epithelial cell kinase during melanoma progression. Cancer Res. 55:2528-2532(1995) |
| Cross-references |
| Encyclopedic resources |
Wikidata; Q54831608
|
| Entry history |
| Entry creation | 15-Nov-2017 |
| Last entry update | 10-Apr-2025 |
| Version number | 8 |
|---|